Compulsory licensing remains one of the most closely watched and debated areas of intellectual property law. While used infrequently in many jurisdictions, compulsory licences continue to play an important role in discussions surrounding access to technology, public policy, competition, public health, and the balance between exclusive rights and broader societal interests.
This category covers legal and policy developments relating to compulsory licences and other forms of non-voluntary licensing across patents, copyright, and related rights. Our contributors analyse legislative initiatives, court decisions, administrative actions, and international developments that influence how compulsory licensing frameworks are interpreted and applied in practice.
Topics covered include pharmaceutical and healthcare innovation, standard-essential patents (SEPs), competition law considerations, government use provisions, technology transfer, and emerging debates arising from the digital and green transitions. We also examine developments at the national, regional, and international level, including initiatives discussed within the World Trade Organization (WTO), World Intellectual Property Organization (WIPO), and other policymaking forums.
For IP professionals, policymakers, in-house counsel, and private practitioners, this section provides timely analysis of compulsory licensing developments and their implications for intellectual property strategy, innovation, and market access.
by Dr. Simon Klopschinski
In the wake of the evolving Corona pandemic the German government intends enacting amendments to the German Act on the Prevention and Control of Infectious Diseases in…
On 20 September 2018, the Treasury Laws Amendment (2018 Measures No. 5) Bill 2018 (Bill) was tabled in Australia’s House of Representatives. Among the amendments proposed was the repeal of Section…
On March 28, 2018, the Beijing High Court issued its decision for Iwncomm v. Sony, a high profile case concerning infringement of a standard essential patent (SEP). The appellate court amended the…
In this case the Federal Court of Justice (FCJ) allowed a compulsory licence under a patent for a pharmaceutical active ingredient for the first time ever. The Court held that a public interest in…
In March our partner Hetti Hilge reported on a preliminary injunction by which the Federal Patent Court granted Merck an interlocutory compulsory license for Merck’s HIV drug Isentress in the light…
On March 22, 2017, the Beijing IP Court (the “trial court”) issued a decision on a high-profile case Iwncomm v. Sony concerning infringement of a standard essential patent (SEP). This case has drawn…
by Rachael Cartwright
On 5 April 2017, Mr Justice Birss handed down his highly anticipated, lengthy and potentially controversial judgment on the FRAND licensing and competition law aspects of the…
In a judgment in preliminary proceedings the Bundespatentgericht (German Federal Patent Court) granted the pharmaceutical company Merck the right to use European patent EP 1 422 218 and to continue…
Following the CJEU judgment Huawei vs ZTE (Case C-170/13) of 16 July 2015, the national courts continue refining the requirements for the assertion of standard-essential patents (SEPs).
So far, the…